PDF(Sci-hub)
Abstract：
OBJECTIVE: The objective of this study was to assess the efficacy and safety of denosumab therapy in osteoporotic postmenopausal women who were previously treated with bisphosphonates.
METHODS: Meta-analyses of four available randomised controlled trials that compared osteoporotic patients who switched to denosumab from bisphosphonates (n = 1416) and those who continued bisphosphonates therapy (n = 1411) were included.
RESULTS: The increase in bone mineral density (BMD) of both the spine and hip was significantly higher in patients who shifted to denosumab than in those who continued bisphosphonates. Despite the incidence of adverse events (AEs) and fractures being comparable, treatment withdrawal owing to AEs was significantly less frequent in the denosumab group.
CONCLUSIONS: The outcomes and treatment compliance were improved in postmenopausal osteoporotic women who shifted to denosumab from bisphosphonates.
UNASSIGNED: The replacement of bisphosphonates with denosumab may lead to better therapeutic efficacy and fewer adherence barriers than those with continued usage of bisphosphonates, which in the future may guide the choice of drug therapy in clinics.
METHODS: Meta-analyses of four available randomised controlled trials that compared osteoporotic patients who switched to denosumab from bisphosphonates (n = 1416) and those who continued bisphosphonates therapy (n = 1411) were included.
RESULTS: The increase in bone mineral density (BMD) of both the spine and hip was significantly higher in patients who shifted to denosumab than in those who continued bisphosphonates. Despite the incidence of adverse events (AEs) and fractures being comparable, treatment withdrawal owing to AEs was significantly less frequent in the denosumab group.
CONCLUSIONS: The outcomes and treatment compliance were improved in postmenopausal osteoporotic women who shifted to denosumab from bisphosphonates.
UNASSIGNED: The replacement of bisphosphonates with denosumab may lead to better therapeutic efficacy and fewer adherence barriers than those with continued usage of bisphosphonates, which in the future may guide the choice of drug therapy in clinics.
摘要：
■本研究的目的是评估denosumab治疗在先前使用双膦酸盐治疗的骨质疏松性绝经后妇女中的疗效和安全性。
■对四个可用的随机对照试验进行了荟萃分析，这些试验比较了从双膦酸盐（n=1416）转为denosumab的骨质疏松患者和继续双膦酸盐治疗（n=1411）的患者。
■转向denosumab的患者脊柱和髋部骨密度（BMD）的增加明显高于继续使用双膦酸盐的患者。尽管不良事件（AE）和骨折的发生率相当，在denosumab组中,由于AE导致的治疗停药频率显著降低.
■从双膦酸盐转向denosumab的绝经后骨质疏松妇女的结局和治疗依从性得到改善。
■用denosumab代替双膦酸盐可能会比继续使用双膦酸盐的治疗效果更好，粘附障碍更少。这在将来可能会指导临床药物治疗的选择。
■对四个可用的随机对照试验进行了荟萃分析，这些试验比较了从双膦酸盐（n=1416）转为denosumab的骨质疏松患者和继续双膦酸盐治疗（n=1411）的患者。
■转向denosumab的患者脊柱和髋部骨密度（BMD）的增加明显高于继续使用双膦酸盐的患者。尽管不良事件（AE）和骨折的发生率相当，在denosumab组中,由于AE导致的治疗停药频率显著降低.
■从双膦酸盐转向denosumab的绝经后骨质疏松妇女的结局和治疗依从性得到改善。
■用denosumab代替双膦酸盐可能会比继续使用双膦酸盐的治疗效果更好，粘附障碍更少。这在将来可能会指导临床药物治疗的选择。
